95 related articles for article (PubMed ID: 11494543)
1. [A trial of new interferon therapy for the patients with chronic hepatitis C resistant to interferon therapy].
Arase Y; Kumada H
Nihon Rinsho; 2001 Jul; 59(7):1309-14. PubMed ID: 11494543
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
[TBL] [Abstract][Full Text] [Related]
3. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
[TBL] [Abstract][Full Text] [Related]
4. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
[TBL] [Abstract][Full Text] [Related]
5. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S
Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945
[TBL] [Abstract][Full Text] [Related]
6. Intravenous natural beta-interferon in white patients with chronic hepatitis C who are nonresponders to alpha-interferon.
Montalto G; Tripi S; Cartabellotta A; Fulco M; Soresi M; Di Gaetano G; Carroccio A; Levrero M
Am J Gastroenterol; 1998 Jun; 93(6):950-3. PubMed ID: 9647026
[TBL] [Abstract][Full Text] [Related]
7. The combination therapy of interferon and amantadine hydrochloride for patients with chronic hepatitis C.
Nakamura H; Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S
Hepatogastroenterology; 2003; 50(49):222-6. PubMed ID: 12630027
[TBL] [Abstract][Full Text] [Related]
8. Twice-a-day versus once-a-day interferon-beta therapy in chronic hepatitis C.
Kaito M; Yasui-Kawamura N; Iwasa M; Kobayashi Y; Nakagawa N; Fujita N; Ikoma J; Gabazza EC; Watanabe S; Adachi Y
Hepatogastroenterology; 2003; 50(51):775-8. PubMed ID: 12828083
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of natural BALL-1 interferon-alpha treatment for patients with chronic hepatitis C and a possible enhancing effect of a twice-daily starting regimen with interferon-beta.
Ebinuma H; Saito H; Tada S; Nakamoto N; Kurita S; Kitamaura K; Horikawa H; Kumagai N; Tsuchimoto K; Ishii H; Hibi T;
Hepatogastroenterology; 2006; 53(67):94-9. PubMed ID: 16506384
[TBL] [Abstract][Full Text] [Related]
10. [Two-step interferon rebound therapy for refractory chronic hepatitis C].
Kato M; Yuki N; Kaneko A; Yamamoto K; Kasahara A; Masuzawa M; Hayashi N
Nihon Rinsho; 2001 Jul; 59(7):1315-9. PubMed ID: 11494544
[TBL] [Abstract][Full Text] [Related]
11. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
[TBL] [Abstract][Full Text] [Related]
12. Predictors of the efficacy of intravenous natural interferon-beta treatment in chronic hepatitis C.
Fukutomi T; Fukutomi M; Iwao M; Watanabe H; Tanabe Y; Hiroshige K; Kinukawa N; Nakamuta M; Nawata H
Med Sci Monit; 2000; 6(4):692-8. PubMed ID: 11208393
[TBL] [Abstract][Full Text] [Related]
13. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
[TBL] [Abstract][Full Text] [Related]
14. Short-term interferon therapy for chronic hepatitis C patients with low viral load.
Sato Y; Tokuue H; Kawamura N; Nezu-Yajima S; Nakajima H; Ishida H; Takahashi S
Hepatogastroenterology; 2004; 51(58):968-72. PubMed ID: 15239226
[TBL] [Abstract][Full Text] [Related]
15. Initial daily interferon administration can gain more eradication of HCV-RNA in patients with chronic hepatitis C, especially with serum intermediate viral load.
Nakamura H; Ito H; Ogawa H; Takeda A; Kanazawa S; Kuroda T; Yamamoto M; Enomoto H; Kimura Y; Zenda S; Terabayashi M; Saeki K; Noguchi S; Hara H; Uemiya M; Igarashi A; Hayashi E
Hepatogastroenterology; 1999; 46(26):1131-9. PubMed ID: 10370680
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2005 Apr; 75(4):550-8. PubMed ID: 15714492
[TBL] [Abstract][Full Text] [Related]
17. Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.
Arase Y; Ikeda K; Tsubota A; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2004; 47(6):355-61. PubMed ID: 15564748
[TBL] [Abstract][Full Text] [Related]
18. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
[TBL] [Abstract][Full Text] [Related]
19. Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon.
Mazzoran L; Grassi G; Giacca M; Gerini U; Baracetti S; Fanni-Canelles M; Zorat F; Pozzato G
Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):338-42. PubMed ID: 9476188
[TBL] [Abstract][Full Text] [Related]
20. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
